Theratechnologies Inc.
TSX : TH
NASDAQ : THER

Theratechnologies Inc.

September 01, 2011 08:30 ET

Theratechnologies Inc.: Tesamorelin Filed for Marketing Authorization in Argentina

MONTREAL, CANADA--(Marketwire - Sept. 1, 2011) - Theratechnologies Inc. (TSX:TH)(NASDAQ:THER) today announced that an affiliate of Sanofi, its commercial partner, has filed a marketing authorization application for tesamorelin in Argentina with the Ministry of Health's National Administration of Drugs, Foods and Medical Technology (ANMAT).

Tesamorelin is proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies estimates that there are approximately 13,000 HIV-infected patients suffering from excess abdominal fat in Argentina. Currently, there are no approved treatments available for this condition in South America.

"We are committed to maximizing the commercial potential of tesamorelin and this cannot be done without the efficient filing of regulatory applications in new markets. Through our partner, Sanofi, we are making great progress in this regard and we are very pleased," said Mr. John-Michel T. Huss, President and Chief Executive Officer of Theratechnologies. "Argentina and Brazil, where an application was also filed, represent important Latin American markets," concluded Mr. Huss.

Theratechnologies signed a distribution and licensing agreement with an affiliate of Sanofi on December 6, 2010, granting them exclusive commercialization rights for tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy in Latin America, Africa and the Middle East.

Additional applications for tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy are currently under review with regulatory agencies in Europe, Brazil, Canada and Israel.

About Theratechnologies

Theratechnologies (TSX:TH)(NASDAQ:THER) is a specialty pharmaceutical company that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at www.theratech.com. Additional information, including the Annual Information Form and the Annual Report, is also available on SEDAR at www.sedar.com and on the Securities and Exchange Commission's website at www.sec.gov.

Forward-Looking Information

This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation, which statements may contain such words as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions. This forward-looking information includes, but is not limited to, information regarding the potential approval of tesamorelin by ANMAT and other regulatory agencies for the treatment of excess abdominal fat in adult HIV-infected patients with lipodystrophy and the size of the Argentinian market.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, that ANMAT and other regulatory agencies will approve tesamorelin for the treatment of excess abdominal fat in adult HIV-infected patients with lipodystrophy, that no additional clinical trials will be required by ANMAT and other regulatory agencies in order to approve tesamorelin and that tesamorelin will be accepted by the marketplace as a treatment for HIV-associated lipodystrophy if approved by ANMAT. These risks and uncertainties include, but are not limited to, the risk that ANMAT and other regulatory agencies do not approve tesamorelin for the treatment of excess abdominal fat in adult HIV-infected patients with lipodystrophy or that ANMAT or other regulatory agencies require additional clinical studies prior to making any decision regarding the approval or non-approval of tesamorelin.

Theratechnologies refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (AIF) dated February 22, 2011. The AIF is available at www.sedar.com and at www.sec.gov under Theratechnologies' public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents Theratechnologies' expectations as of that date.

Theratechnologies undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contact Information

  • Roch Landriault
    NATIONAL Public Relations
    514-843-2345